NASDAQ:ATHA Athira Pharma (ATHA) Stock Price, News & Analysis $3.31 -0.01 (-0.30%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.25▼$3.3850-Day Range$2.19▼$3.4052-Week Range$1.33▼$4.30Volume41,360 shsAverage Volume278,616 shsMarket Capitalization$126.87 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Athira Pharma alerts: Email Address Athira Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside474.0% Upside$19.00 Price TargetShort InterestHealthy3.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 2 Articles This WeekInsider TradingAcquiring Shares$100,208 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.79) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.43 out of 5 starsMedical Sector317th out of 936 stocksBiological Products, Except Diagnostic Industry45th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAthira Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAthira Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Athira Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.06% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Athira Pharma has recently decreased by 1.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHA. Previous Next 4.0 News and Social Media Coverage News SentimentAthira Pharma has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Athira Pharma this week, compared to 1 article on an average week.Search Interest3 people have searched for ATHA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,208.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Athira Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athira Pharma are expected to decrease in the coming year, from ($2.79) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Athira Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Athira Pharma Stock (NASDAQ:ATHA)Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Read More ATHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHA Stock News HeadlinesJune 26, 2024 | insidertrades.comAthira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano Purchases 15,000 SharesJuly 16, 2024 | americanbankingnews.comAthira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Growth in Short InterestJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 12, 2024 | globenewswire.comAthira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease PatientsJune 10, 2024 | prnewswire.comGlancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)May 29, 2024 | globenewswire.comAthira Pharma to Participate in Upcoming June ConferencesMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Athira Pharma Amid Promising Alzheimer’s Drug Developments and Strategic AdvancementsMay 17, 2024 | globenewswire.comAthira Pharma Announces Proposed Settlement of Stockholder Derivative ActionJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 17, 2024 | bizjournals.comAthira names new chief medical officer ahead of release of key trial dataMay 16, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesMay 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)May 16, 2024 | msn.comATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024May 15, 2024 | globenewswire.comAthira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesMay 2, 2024 | globenewswire.comAthira Pharma to Participate in Upcoming May ConferencesApril 27, 2024 | seekingalpha.comATHA Athira Pharma, Inc.April 23, 2024 | finance.yahoo.comOne Athira Pharma Insider Raised Their Stake In The Previous YearApril 17, 2024 | msn.comAthira Pharma (ATHA) Price Target Increased by 7.49% to 7.57See More Headlines Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+470.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.59% Return on Assets-67.70% Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio5.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book0.97Miscellaneous Outstanding Shares38,329,000Free Float30,740,000Market Cap$127.64 million OptionableOptionable Beta2.90 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Mark J. Litton M.B.A. (Age 56)Ph.D., President, CEO & Director Comp: $882.7kMr. Andrew W. Gengos (Age 60)CFO & Chief Business Officer Comp: $396.16kMs. Rachel P. Lenington M.B.A. (Age 51)Chief Development Officer & COO Comp: $578kDr. Kevin Church Ph.D. (Age 39)Chief Scientific Officer Comp: $123.67kMs. Julie RathbunHead of Investor RelationsMr. Mark F. Worthington J.D. (Age 58)General Counsel & Corporate Secretary Comp: $503.83kMs. Samantha WillingChief People OfficerDr. Javier San Martin M.D. (Age 59)Chief Medical Officer More ExecutivesKey CompetitorsVaxartNASDAQ:VXRTAgenusNASDAQ:AGENPassage BioNASDAQ:PASGAligos TherapeuticsNASDAQ:ALGSValnevaNASDAQ:VALNView All CompetitorsInsiders & InstitutionsKelly A RomanoBought 27,400 shares on 6/24/2024Total: $66,308.00 ($2.42/share)Kelly A RomanoBought 15,000 shares on 6/21/2024Total: $33,900.00 ($2.26/share)Jacobs Levy Equity Management Inc.Bought 227,278 shares on 5/16/2024Ownership: 1.298%Vanguard Group Inc.Sold 64,020 shares on 5/10/2024Ownership: 4.264%Acadian Asset Management LLCBought 405,793 shares on 5/10/2024Ownership: 1.435%View All Insider TransactionsView All Institutional Transactions ATHA Stock Analysis - Frequently Asked Questions How have ATHA shares performed this year? Athira Pharma's stock was trading at $2.43 at the beginning of 2024. Since then, ATHA shares have increased by 36.2% and is now trading at $3.31. View the best growth stocks for 2024 here. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.11. When did Athira Pharma IPO? Athira Pharma (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager. Who are Athira Pharma's major shareholders? Top institutional investors of Athira Pharma include Concourse Financial Group Securities Inc.. Insiders that own company stock include Perceptive Advisors Llc, Glenna Mileson, Mark James Litton, Andrew Gengos, Kelly A Romano, Hans Moebius, Mark Worthington, Rachel Lenington and James A Johnson. View institutional ownership trends. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA) and Alibaba Group (BABA). This page (NASDAQ:ATHA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
